国内首份！一张海外版药品价格证明 如何帮小微药企敲开创新药出海大门？

Core Viewpoint - The introduction of the drug price registration system in China provides a new opportunity for domestic innovative pharmaceutical companies to establish pricing for their products before entering international markets, as evidenced by the issuance of the first overseas drug price certificate for a new drug targeting infant vascular tumors [1][5]. Group 1: Overview of the Drug Price Registration System - The drug price registration system, launched by the National Healthcare Security Administration, aims to assist Chinese innovative drugs in going global by providing a platform for price registration independent of the healthcare insurance system [1][7]. - The first overseas drug price certificate was awarded to the drug malate timolol gel, which is the first original drug for external treatment of infant vascular tumors [1][4]. Group 2: Focus on Small Pharmaceutical Enterprises - Small original research pharmaceutical companies are the primary beneficiaries of the drug price registration system, as they often face challenges in establishing pricing for their products in international markets [3][5]. - Beijing Meirsen Pharmaceutical Technology Development Co., Ltd., a small company that transitioned from raw material production to innovative drug development, received the first overseas price certificate for its malate timolol gel [4][5]. Group 3: Importance of Pricing and Market Strategy - The pricing registration process involves a comprehensive pricing system that includes expert consultations and economic analysis to ensure the credibility of the registered price [7][8]. - The company plans to leverage the overseas price certificate to expand its business into Southeast Asia and eventually Europe, as entering larger markets like the U.S. can be financially burdensome for smaller firms [8][9].